De Rucci Healthy Sleep Co. Ltd. (001323) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of De Rucci Healthy Sleep Co. Ltd. stock ¥20.13, price ¥17.68, upside +13.9%, quality 57 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
52‑month range ¥15.39 – ¥41.37 · fair‑value band ¥14.19 – ¥28.87 · the ¥17.68 price screens below the ¥20.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow De Rucci Healthy Sleep Co. in your weekly email
Every Wednesday you see whether De Rucci Healthy Sleep Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
De Rucci Healthy Sleep Co., Ltd., together with its subsidiaries, engages in the research, design, development, production, and sale of healthy sleep systems in China and internationally.
Show moreShow less
The company offers mattresses, bed frames, sofas, beddings, and its supporting home furnishings under the DeRUCCI, CALIAITALIA, CALIA, V6 Home Furnishings, and SleepDesigns brands.
It also engages in the provision of delivery, installation, repair, and maintenance; consulting; research and development; and investing services. The company sells its products through its online store. De Rucci Healthy Sleep Co., Ltd. was founded in 2004 and is headquartered in Dongguan, China.
Stock analysis
De Rucci Healthy Sleep Co. Ltd. (001323) currently trades at ¥17.68, while our model-based Fair Value estimate is ¥20.13, implying the stock looks roughly 12% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥21.97 per share, and 7 of the 24 models we run sit above the ¥17.68 price.
Bear case: the Growth DCF group reads lowest at ¥10.38, and 17 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥14.19 (bear) to ¥28.87 (bull), the price of ¥17.68 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Consumer Cyclical sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
De Rucci Healthy Sleep Co. Ltd. reported revenue of 5.2B CNY in FY2025 versus 6.5B CNY in FY2021, a compound −5.2%/yr. Reported net income was 536M CNY in FY2025, compounding −6.0%/yr from FY2021.
Key figures
Market cap 7.7B CNY (≈ $1.2B) Small · P/E ratio 24.6 · P/S ratio 1.49 · EPS (TTM) ¥0.7200 · Dividend yield 5.7% · Net margin 6.0% · Return on equity 6.9% · Return on assets (EBIT) 12.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 37% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at −24% fair-value upside, at 14%, 001323 screens cheaper than that median.
Fair Value models
Bear¥14.19Fair Value ¥20.13Bull¥28.87
Price ¥17.68 · Upside +13.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥6.09¥7.19¥9.1180
Growth DCF¥6.21¥7.26¥8.9578
Owner Earnings¥8.62¥10.52¥13.8476
All 24 models by family
DCF Models
FCF DCF¥6.09¥7.19¥9.1180
Owner Earnings¥8.62¥10.52¥13.8476
5Y Revenue Exit¥9.44¥13.41¥19.2370
5Y EBITDA Exit¥12.03¥17.87¥25.6573
5Y P/E Exit¥14.14¥21.52¥30.3368
10Y Revenue Exit¥7.74¥10.48¥13.5366
10Y EBITDA Exit¥9.45¥13.10¥17.1167
10Y P/E Exit¥10.66¥15.23¥19.7363
Earnings-Based
Graham-Dodd¥8.37¥10.81¥12.3565
EPV¥9.57¥10.57¥11.4174
Dividend Discount
Gordon GGM¥11.18¥12.10¥13.4867
DDM Multi-Stage¥11.18¥13.63¥16.7465
Multiples
P/E Multiple¥20.31¥27.08¥33.8563
P/S Multiple¥10.81¥14.42¥18.0258
P/B Multiple¥28.40¥37.87¥47.3455
EV/EBIT¥16.57¥21.86¥27.1566
EV/EBITDA¥16.73¥22.07¥27.4267
EV/Revenue¥10.78¥15.11¥19.4354
Asset-Based
NCAV (Graham)¥1.24¥1.89¥2.3654
Growth DCF
Growth DCF¥6.21¥7.26¥8.9578
Rev-Margin DCF¥9.44¥13.50¥18.4171
Economic Profit
Residual Income¥9.17¥10.27¥12.2974
ROIC Compounder¥9.57¥10.61¥11.7170
Growth Earnings
Growth-Adj P/E¥14.32¥20.45¥26.5965
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.2%
Dividend (yield on the price)5.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 10%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +16.7% a year for the price and +2.4% for the forecasts.
Compare De Rucci Healthy Sleep Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Furnishings, Fixtures & Appliances · 297 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "De Rucci Healthy Sleep Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/001323
Frequently asked questions
Is De Rucci Healthy Sleep Co. Ltd. (001323) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥20.13 versus a price of ¥17.68, about +14% upside (undervalued).
What is the fair value of 001323?
Our model-based fair value for De Rucci Healthy Sleep Co. Ltd. is ¥20.13 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥17.68.
What is the quality score of 001323?
De Rucci Healthy Sleep Co. Ltd. has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for De Rucci Healthy Sleep Co. Ltd. (001323)?
Our model-based price target is the fair value of ¥20.13 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario ¥14.19, optimistic scenario ¥28.87. It is a calculation from audited fundamentals, not an analyst target.
What is the De Rucci Healthy Sleep Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥20.13, about +14% upside versus a price of ¥17.68 (undervalued). Cautious scenario ¥14.19, optimistic scenario ¥28.87. The calculation is refreshed regularly with new filings.
What is the revenue of De Rucci Healthy Sleep Co. Ltd. (001323)?
De Rucci Healthy Sleep Co. Ltd. reported trailing-twelve-month revenue of about 5.2B CNY (latest available figure, as of Nov 6, 2026).
Does De Rucci Healthy Sleep Co. Ltd. pay a dividend?
De Rucci Healthy Sleep Co. Ltd. currently shows a dividend yield of 5.66% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of De Rucci Healthy Sleep Co. Ltd. (001323) and when is the ex-dividend date?
De Rucci Healthy Sleep Co. Ltd. pays a dividend of ¥1.00 per share a year, a dividend yield of 5.7%. The last ex-dividend date was Jun 8, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 139% of earnings. Free cash flow covers the dividend 0.37 times. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What growth is priced into De Rucci Healthy Sleep Co. Ltd. (001323)?
For today's price to be fair in a discounted-cash-flow model, De Rucci Healthy Sleep Co. Ltd. would have to grow free cash flow by +18.6 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 001323 use?
Our models discount De Rucci Healthy Sleep Co. Ltd. at 10.4 %: a base by market capitalisation (small), damped by beta 0.33, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For De Rucci Healthy Sleep Co. Ltd. that is +18.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has De Rucci Healthy Sleep Co. Ltd. (001323) delivered so far?
Over the past 5 years revenue at De Rucci Healthy Sleep Co. Ltd. grew +3.3 % a year. The price currently implies free-cash-flow growth of +18.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of De Rucci Healthy Sleep Co. Ltd. (001323) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into De Rucci Healthy Sleep Co. Ltd. (+18.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of De Rucci Healthy Sleep Co. Ltd. (001323)?
The free-cash-flow yield on the price is 2.11 %: that much free cash flow De Rucci Healthy Sleep Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of De Rucci Healthy Sleep Co. Ltd. (001323)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For De Rucci Healthy Sleep Co. Ltd. it is ¥20.13 per share (as of Nov 6, 2026), against a price of ¥17.68. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is De Rucci Healthy Sleep Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 001323 trades below its calculated fair value: price ¥17.68, fair value ¥20.13, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 001323?
No. The price is what the market pays today (¥17.68); the fair value is what the company's own numbers justify (¥20.13). For De Rucci Healthy Sleep Co. Ltd. the two are ¥2.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is De Rucci Healthy Sleep Co. Ltd. worth?
The market values De Rucci Healthy Sleep Co. Ltd. at about 7.7B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥17.68; our models calculate a fair value of ¥20.13 per share.
What do the bullish and bearish scenarios say about 001323?
Our models span a range for De Rucci Healthy Sleep Co. Ltd.: cautious scenario ¥14.19, base ¥20.13, optimistic ¥28.87 per share (as of Nov 6, 2026, price ¥17.68). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 001323?
De Rucci Healthy Sleep Co. Ltd. trades at a price-to-earnings ratio of 24.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥20.13 is built from several models across several years. Other multiples: P/B 1.7, P/S 1.5, EV/EBITDA 13.1.
How solid is the balance sheet of De Rucci Healthy Sleep Co. Ltd. (001323)?
Balance-sheet figures for De Rucci Healthy Sleep Co. Ltd. (as of Nov 6, 2026): return on equity 6.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 001323 from its 52-week high?
De Rucci Healthy Sleep Co. Ltd. trades at ¥17.68, about 37% below its 52-week high of ¥27.94 and 15% above the low of ¥15.39 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥20.13 is for.
Which stocks are comparable to De Rucci Healthy Sleep Co. Ltd.?
From the same area (Consumer Cyclical) we also value Midea Group, Gree Electric Appliances, Inc, SharkNinja, Inc, Haier Smart Home Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is De Rucci Healthy Sleep Co. Ltd. stock attractive at the current price?
The data as of Nov 6, 2026: price ¥17.68, calculated fair value ¥20.13 (+14%), Quality Score 57/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 001323 calculated?
We run De Rucci Healthy Sleep Co. Ltd. through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥20.13 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. De Rucci Healthy Sleep Co. Ltd. currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of De Rucci Healthy Sleep Co. Ltd. (001323)?
The closing price on Nov 6, 2026 was ¥17.68. Our model-based fair value is ¥20.13, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with De Rucci Healthy Sleep Co. Ltd. right now?
A fairly wide model range (¥14.19 to ¥28.87) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of De Rucci Healthy Sleep Co. Ltd.
How large is the market capitalisation of De Rucci Healthy Sleep Co. Ltd. (001323)?
The market capitalisation of De Rucci Healthy Sleep Co. Ltd. is 7.7B CNY (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of De Rucci Healthy Sleep Co. Ltd. (001323)?
The price-to-sales ratio of De Rucci Healthy Sleep Co. Ltd. is 1.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of De Rucci Healthy Sleep Co. Ltd. (001323)?
Earnings per share at De Rucci Healthy Sleep Co. Ltd. are ¥0.7200 (price ÷ EPS = P/E 24.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of De Rucci Healthy Sleep Co. Ltd. (001323)?
The dividend yield of De Rucci Healthy Sleep Co. Ltd. is 5.7% (payout 139%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of De Rucci Healthy Sleep Co. Ltd. (001323)?
The net margin of De Rucci Healthy Sleep Co. Ltd. is 6.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of De Rucci Healthy Sleep Co. Ltd. (001323)?
The return on equity (ROE) of De Rucci Healthy Sleep Co. Ltd. is 6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of De Rucci Healthy Sleep Co. Ltd. (001323)?
On an EBIT basis the return on assets of De Rucci Healthy Sleep Co. Ltd. is 12.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of De Rucci Healthy Sleep Co. Ltd. (001323)?
The operating margin of De Rucci Healthy Sleep Co. Ltd. is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at De Rucci Healthy Sleep Co. Ltd. (001323)?
Revenue at De Rucci Healthy Sleep Co. Ltd. is growing −4.8% versus a year earlier (3y avg −3.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at De Rucci Healthy Sleep Co. Ltd. (001323)?
Earnings per share at De Rucci Healthy Sleep Co. Ltd. are growing −47.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does De Rucci Healthy Sleep Co. Ltd. (001323) hold?
De Rucci Healthy Sleep Co. Ltd. holds more cash than debt, 301M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch De Rucci Healthy Sleep Co. Ltd. in the live analysis
One click puts De Rucci Healthy Sleep Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026